wound healing

The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment.

Despite encouraging preclinical safety and efficacy data for its RNAi-based hepatitis C treatment, Somagenics has decided to step back from its previous plan to push the agent into phase I testing this year as it waits to see how more advanced small-molecule therapies fare in lat

Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China, a company official told Gene Silencing News this week.

By Doug Macron
The National Institutes of Health last month handed out nearly $1.3 million in grant funding to support four research projects focused on developing siRNA-delivery technologies.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.